Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Aurelina Aguiar de Aguiar"'
Autor:
Betânia Leite, Camile Giaretta Sachetti, Luciana Simões Camara Leão, Aurelina Aguiar de Aguiar, Daniela Fortunato Rêgo, Lenilson Pereira Gonçalves, Dalila Fernandes Gomes, Roberta Borges Silva, Cecília Menezes Farinasso
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:29-30
IntroductionThe Department of Sciences and Technology (Decit) of the Brazilian Government has played a vital role in drafting of the National Policy for Biologic Medicines. Decit has provided methodological support to the working group, conducting a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e06b71ac8a13fe7f5dff2156a8a2b54
https://doi.org/10.1017/s0266462319001600
https://doi.org/10.1017/s0266462319001600
Autor:
Roberta Borges Silva, Aurelina Aguiar de Aguiar, Luciana Simões, Daniela Fortunato Rêgo, Cecília Menezes Farinasso, Camile Giaretta Sachetti, Camara Leão, Dalila Fernandes Gomes
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:97-97
IntroductionAdverse conditions during pregnancy, such as myelomeningocele (MMC), fetal-fetal transfusion syndrome (STFF) and congenital heart disease (CHD) not only significantly increase the risk of fetal death, but also increase the occurrence of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3063fffe41e92bdc4888e276f5b790b1
https://doi.org/10.1017/s026646231900343x
https://doi.org/10.1017/s026646231900343x
Autor:
Dalila Fernandes Gomes, Aurelina Aguiar de Aguiar, Lenilson Pereira Gonçalves, Camile Giaretta Sachetti, Cecília Menezes Farinasso, Daniela Fortunato Rêgo, Luciana Simões Camara Leão, Betânia Leite, Roberta Borges Silva
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:30-30
IntroductionDue to the high judicialization rates which pressure the financing of biologic medicines by the Brazilian Unified Health System (Sistema Único de Saúde - SUS), it has been decided to formulate the National Policy for Biologic Medicines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8933dc017e671b12ff494f3fa2d5f977
https://doi.org/10.1017/s0266462319001612
https://doi.org/10.1017/s0266462319001612
Autor:
Daniela Fortunato Rêgo, Aurelina Aguiar de Aguiar, Lenilson Pereira Gonçalves, Camara Leão, Luciana Simões, Roberta Borges Silva, Betânia Leite, Cecília Menezes Farinasso, Dalila Fernandes Gomes, Camile Giaretta Sachetti
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:92-92
IntroductionThe elevated costs with biologic products threaten the sustainability of health services, and, therefore, the access to these medicines in the perspectives of user, health professional, health manager and system. The entry of biosimilar p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12dd86de38115ee72af57ecc94b041ab
https://doi.org/10.1017/s0266462319003271
https://doi.org/10.1017/s0266462319003271